Delving into the Latest Updates on Paranta Biosciences Ltd. with Synapse

Overview

Author: Cursons, Joseph ; Davis, Melissa J. ; Souza-Fonseca-Guimaraes, Fernando ; Schuster, Iona S. ; Harrison, Craig ; Kita, Badia ; Hediyeh-Zadeh, Soroor ; Rautela, Jai ; Huntington, Nicholas D. ; de Oliveira, Carolina C. ; Hennessy, Robert ; Dagley, Laura F. ; Hutchinson, Dana S. ; Webb, Andrew I. ; Degli-Esposti, Mariapia A. ; Delconte, Rebecca B. ; Vivier, Eric

Activin-A inhibits NK cell effector functions and suppresses antimelanoma immunity.

01 Dec 2018·Journal of Translational MedicineQ2 · MEDICINE

Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection

Q2 · MEDICINE

ArticleOA

Author: de Kretser, David M ; Ludlow, Helen ; Lewis, Don P ; Hedger, Mark P ; Kita, Badia ; Groome, Nigel P ; Lidbury, Brett A ; Richardson, Alice M

BACKGROUNDMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is clinically defined and characterised by persistent disabling tiredness and exertional malaise, leading to functional impairment.METHODSThis study introduces the weighted standing time (WST) as a proxy for ME/CFS severity, and investigates its behaviour in an Australian cohort. WST was calculated from standing time and subjective standing difficulty data, collected via orthostatic intolerance assessments. The distribution of WST for healthy controls and ME/CFS patients was correlated with the clinical criteria, as well as pathology and cytokine markers. Included in the WST cytokine analyses were activins A and B, cytokines causally linked to inflammation, and previously demonstrated to separate ME/CFS from healthy controls. Forty-five ME/CFS patients were recruited from the CFS Discovery Clinic (Victoria) between 2011 and 2013. Seventeen healthy controls were recruited concurrently and identically assessed.RESULTSWST distribution was significantly different between ME/CFS participants and controls, with six diagnostic criteria, five analytes and one cytokine also significantly different when comparing severity via WST. On direct comparison of ME/CFS to study controls, only serum activin B was significantly elevated, with no significant variation observed for a broad range of serum and urine markers, or other serum cytokines.CONCLUSIONSThe enhanced understanding of standing test behaviour to reflect orthostatic intolerance as a ME/CFS symptom, and the subsequent calculation of WST, will encourage the greater implementation of this simple test as a measure of ME/CFS diagnosis, and symptom severity, to the benefit of improved diagnosis and guidance for potential treatments.

25 Jul 2018·Science Translational MedicineQ1 · MEDICINE

Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy

Q1 · MEDICINE

Article

Author: Jayasekara, W. Samantha N. ; Barrow, Ross ; Hedger, Mark P. ; Watkins, D. Neil ; Han, Jeremy Z. R. ; Gonzalez-Rajal, Alvaro ; Martelotto, Luciano G. ; Hastings, Jordan F. ; de Kretser, David M. ; Marini, Kieren D. ; Kumar, Beena ; Kita, Badia ; Boolell, Vishal ; Alamgeer, Muhammad ; Harrison, Craig A. ; Waugh, Todd ; Robinson, Bruce W. ; Rossello, Fernando J. ; Wu, Jianmin ; Croucher, David R. ; Chin, Venessa ; Marquez, Cesar ; Lee, Hong Ching ; McCloy, Rachael A. ; Sweet-Cordero, E. Alejandro ; Ganju, Vinod ; Szczepny, Anette ; Burgess, Andrew ; Lorensuhewa, Nirmal ; Cain, Jason E. ; Vaghjiani, Vijesh ; Kostyrko, Kaja ; Oakes, Samantha R.

Inhibition of activin signaling enhances the efficacy and safety of platinum chemotherapy in lung adenocarcinoma models.

100 Deals associated with Paranta Biosciences Ltd.

Login to view more data

100 Translational Medicine associated with Paranta Biosciences Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data